Endocyte inc (ECYT)
Balance Sheet / TTM
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Assets
Current assets:
Cash and cash equivalents

67,268

25,044

89,831

18,559

47,178

64,928

33,660

31,228

34,732

26,588

40,156

15,431

31,015

28,035

29,238

45,533

48,572

31,568

32,854

52,846

51,245

64,216

36,032

33,996

36,728

66,653

101,831

61,352

66,640

29,722

16,872

Short-term investments

276,942

141,747

83,292

78,912

55,901

53,466

93,901

106,979

111,983

128,020

123,170

158,168

141,112

145,317

130,941

79,536

79,997

89,533

91,318

70,434

59,908

46,519

98,774

141,840

152,701

139,740

16,055

66,732

72,228

54,171

0

Receivables

48

25

-

273

27

8

5

55

20

2

0

8

84

0

119

706

3,946

5,278

5,354

6,353

8,332

8,917

6,913

5,689

5,738

4,823

-

0

-

-

-

Prepaid expenses

1,552

1,564

1,259

751

1,159

784

1,526

1,737

1,492

968

1,197

772

1,038

1,055

1,368

609

1,130

1,482

4,552

3,200

3,823

3,173

3,156

2,799

1,701

2,236

2,195

1,122

807

1,194

2,637

Other assets

5,500

178

172

77

125

129

283

255

311

259

306

493

446

636

520

652

680

810

953

496

603

549

608

498

510

400

174

548

325

462

539

Total current assets

351,311

168,561

174,556

98,572

104,392

119,317

129,376

140,255

148,540

155,839

164,831

174,875

173,697

175,044

162,188

127,038

134,327

128,674

135,034

133,331

123,914

123,376

145,485

184,824

197,380

213,854

120,257

129,756

140,002

85,552

20,050

Long-term investments

-

-

-

-

-

-

-

-

-

-

-

-

8,173

15,220

36,603

81,761

82,535

98,097

7,370

25,571

48,037

59,073

51,095

25,540

15,277

5,084

-

0

-

-

-

Property and equipment, net

1,556

1,745

1,942

2,182

2,445

2,615

2,982

3,205

3,396

3,506

3,586

3,398

3,565

3,672

3,790

3,970

4,145

4,162

3,856

3,839

3,440

3,370

3,208

3,166

2,531

2,149

1,418

1,107

858

772

863

Other noncurrent assets

2,336

1,861

178

7

7

7

27

33

49

61

127

111

181

31

31

31

31

11

219

114

179

381

471

546

631

676

723

811

872

597

300

Total assets

355,204

172,168

176,678

100,762

106,845

121,940

132,386

143,494

151,986

159,407

168,545

178,385

185,618

193,968

202,613

212,801

221,038

230,945

146,479

162,857

175,571

186,202

200,260

214,078

215,821

221,766

122,399

131,675

141,733

86,922

21,214

Liabilities and Stockholders Equity
Current liabilities:
Accounts payable

1,095

1,323

1,414

376

395

1,235

1,546

1,381

1,516

1,360

1,243

1,262

956

1,541

1,611

1,234

1,106

3,490

3,665

5,435

5,001

2,996

2,323

3,647

2,080

1,942

2,403

2,125

4,591

3,994

755

Accrued wages and benefits

2,884

2,120

1,120

2,533

1,542

1,521

1,143

2,705

1,701

1,677

1,267

3,272

2,706

1,735

1,390

2,567

2,170

2,173

1,663

3,065

2,263

1,494

1,009

2,426

1,555

975

742

1,032

779

888

155

Accrued clinical trial expenses

1,512

1,053

1,007

689

1,360

1,792

1,207

861

902

885

1,028

804

1,077

1,509

1,272

2,336

5,131

7,381

3,932

3,728

3,605

5,061

3,048

2,486

1,960

1,146

-

665

-

-

-

Accrued expenses and other liabilities

2,182

1,455

1,070

946

1,048

690

1,017

613

430

621

798

850

641

675

1,252

745

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

103

105

99

111

140

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

868

2,168

2,709

1,668

1,673

1,875

2,996

1,902

1,346

816

257

1,540

-

-

1,305

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

50

45,733

59,746

58,105

56,279

53,646

51,993

48,546

46,808

-

0

-

-

-

Current portion of other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

15

18

18

16

15

-

12

-

-

-

-

-

-

775

Current portion of capital lease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12

-

12

12

-

0

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,550

-

-

-

-

Current portion of long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,015

-

0

5,606

4,318

Preferred stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

223

Total current liabilities

7,674

5,953

4,613

4,546

4,347

5,239

4,915

5,562

4,551

4,544

4,337

6,188

5,382

5,461

5,526

6,884

9,340

15,280

57,722

73,663

70,666

67,722

63,037

62,470

55,501

51,701

6,072

5,470

5,471

10,600

7,673

Deferred revenue, net of current portion

332

348

363

731

744

756

769

781

794

806

819

831

844

856

869

881

894

906

919

931

15,457

28,139

40,235

51,993

60,682

70,201

-

0

-

-

-

Other liabilities, net of current portion

-

-

-

-

-

-

-

2

7

11

15

18

21

25

27

30

25

27

29

33

38

43

-

42

-

-

-

-

637

637

-

Capital lease, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49

-

19

22

-

0

-

-

-

Long-term debt, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

11,827

12,833

12,186

7,922

11,123

Subordinated notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

9,529

Total liabilities

8,007

6,302

4,976

5,278

5,091

5,996

5,684

6,346

5,352

5,362

5,172

7,039

6,248

6,343

6,423

7,797

10,260

16,214

58,671

74,628

86,162

95,905

103,321

114,505

116,203

121,926

17,899

18,303

18,295

19,160

28,325

Stockholders equity:
Convertible preferred stock, $0.001 par value; 14,310,992 shares authorized; 11,747,563 shares issued and outstanding at December 31, 2010

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

89,799

Common stock: $0.001 par value, 100,000,000 shares authorized; 48,203,529 and 81,323,300 shares issued and outstanding at December 31, 2017 and September 30, 2018

81

69

69

48

47

42

42

42

42

42

42

42

41

41

41

41

41

41

36

36

36

36

35

35

35

35

35

35

35

29

1

Additional paid-in capital

688,527

494,612

488,929

404,454

402,100

393,060

392,092

390,768

389,117

387,756

383,187

381,118

379,245

377,551

375,492

373,571

371,197

369,437

264,789

262,060

260,374

258,330

256,624

255,356

254,558

253,658

252,837

251,942

251,234

183,478

1,156

Accumulated other comprehensive loss

-22

-34

-79

-64

-4

-34

-53

-41

31

96

30

-79

23

-28

-9

-143

-75

-38

48

56

20

-87

33

72

66

-49

-2

-6

13

29

0

Retained deficit

-341,389

-328,782

-317,217

-308,954

-300,390

-277,123

-265,378

-253,622

-242,557

-233,850

-219,887

-209,734

-199,940

-189,939

-179,335

-168,465

-160,384

-154,709

-177,066

-173,924

-171,022

-167,981

-159,753

-155,892

-155,043

-153,804

-148,370

-138,600

-127,846

-115,776

-98,068

Total stockholders equity

347,196

165,866

171,701

95,484

101,753

115,944

126,701

137,147

146,633

154,044

163,372

171,346

179,369

187,625

196,190

205,004

210,778

214,730

87,807

88,228

89,408

90,297

96,939

99,573

99,617

99,840

104,499

113,371

123,438

67,761

-96,911

Total liabilities and stockholders equity

355,204

172,168

176,678

100,762

106,845

121,940

132,386

143,494

151,986

159,407

168,545

178,385

185,618

193,968

202,613

212,801

221,038

230,945

146,479

162,857

175,571

186,202

200,260

214,078

215,821

221,766

122,399

131,675

141,733

86,922

21,214